Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial

CONCLUSION: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.PMID:37843857 | DOI:10.1158/1078-0432.CCR-23-1966

Source: Clinical Cancer Research - October 16, 2023 Category: Cancer & Oncology Authors: Raphael Koch Lianne Haveman Ruth Ladenstein B énédicte Brichard Heribert Juergens So ňa Cyprová Henk van den Berg Wolf Hassenpflug Anna Raciborska Torben Ek Daniel Baumhoer Gerlinde Egerer Leo Kager Marleen Renard Peter Hauser Stefan Burdach Judith V Source Type: research